公司概述
HeartBeam, Inc. operates within the healthcare sector, specifically focusing on the health information services industry, where it develops and commercializes electrocardiogram solutions designed to detect and monitor cardiac diseases outside of traditional healthcare facilities. The company's primary product offering is the HeartBeam System, a cable-free and ambulatory 12L ECG device that enables continuous cardiac monitoring for patients in non-clinical settings. As of the latest data available, the company maintains a market capitalization of $48.48 million and employs 16 individuals to execute its business strategy. These valuation figures indicate that HeartBeam, Inc. is a small-cap entity with limited market penetration relative to established medical technology peers, reflecting a niche position in the specialized diagnostic equipment market rather than broad consumer reach.
财务健康
The financial statements for HeartBeam, Inc. reveal a significant operational deficit, with Net Income (TTM) recorded at $-21,015,000 and EBITDA standing at $-21,099,000, while annual Revenue (TTM) is listed as N/A. The substantial gap between the reported Net Income and EBITDA suggests that the company's cost structure involves significant non-operating expenses or interest costs that erode profitability before reaching the bottom line, although the absence of specific revenue data prevents a precise gross margin analysis on a per-unit basis. Free Cash Flow for the trailing twelve months stands at $-6,918,982, indicating that the company is currently burning cash, which limits its financial flexibility for capital expenditures or acquisitions without external financing. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported as 0.0%, a figure that typically indicates either a lack of finalized audited data for specific periods or a severe erosion of margins where costs consume total revenue. The balance sheet shows a cash position of $4.38 million against $0 in debt, resulting in a Debt to Equity ratio of N/A, which implies the company is currently unleveraged and not utilizing borrowed capital to finance its operations. The Current Ratio is 1.45, suggesting that the company possesses sufficient liquid assets to cover its short-term liabilities, providing a baseline of liquidity despite the negative cash flow generation. Furthermore, the Return on Equity is -987.3% and the Return on Assets is -289.8%, metrics that reveal management has been unable to generate positive returns on its shareholders' capital or asset base, highlighting the challenges inherent in scaling a high-cost medical technology startup.
估值评估
Valuation multiples for HeartBeam, Inc. present a complex picture given the company's lack of profitability, with the P/E Ratio (TTM) listed as N/A and the Forward P/E showing a negative value of -2.23. The discrepancy between a non-existent trailing earnings multiple and a negative forward multiple implies that analysts or market participants are pricing in an expected turnaround in earnings trajectory, though the negative forward P/E confirms that projected earnings remain negative in the near term. The Price to Book ratio is significantly elevated at 18.15, indicating that the market is valuing the company at a substantial premium over its net asset value, which often reflects investor optimism regarding future intangible assets or proprietary technology rather than current book value. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-2.09) further underscore the difficulty in applying traditional valuation models to a company with no revenue and negative earnings, suggesting the stock is priced purely on potential future cash flows. The stock has exhibited significant volatility, trading between a 52-Week High of $4.00 and a 52-Week Low of $0.54. Relative to this range, the current market price sits at a level that suggests high sensitivity to market sentiment, though the exact percentage deviation from the high requires real-time price data not provided in the facts. The Beta value of -0.64 is anomalous for a healthcare stock, indicating an inverse correlation with the broader market where price movements move counter to general market trends, likely due to the small-cap status and specific trading volume characteristics.
Growth & Income
Growth metrics for HeartBeam, Inc. are currently unavailable as both Revenue Growth (YoY) and Earnings Growth (YoY) are listed as N/A, which prevents a direct comparison of whether earnings are growing faster or slower than revenue. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available earnings—or in this case, absorbs all losses—back into the business rather than distributing income to shareholders. This non-dividend strategy is typical for early-stage medical technology firms that prioritize product development and commercialization over shareholder returns. Consequently, the overall growth and income profile of HeartBeam, Inc. is characterized by a complete reliance on capital appreciation potential rather than current yield or historical growth rates, leaving investors exposed to the risks associated with high burn rates and uncertain revenue trajectories without the cushion of a dividend safety net.